This need has already been partially addressed with SMO inhibitors in MB (clinical responses correlate to the genomic heterogeneity within SHH subgroup), but we are still far away from this scenario in the majority of tumours (including RMS), since no predictive Hh-pathway biomarkers have been identified to date. The gene discussed is SMO; the disease is neoplasm.